RUTH.AQSE

Rutherford Health Plc
Rutherford Health - Rutherford Cancer Centres and Bupa partner
8th November 2021, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5522R
Rutherford Health PLC
08 November 2021
 

 

Rutherford Health Plc

 

Bupa and Rutherford Cancer Centres partner
to opennew health clinics

 

8 November 2021: Rutherford Health plc (AQSE: RUTH, the "Group"), a leading UK provider of innovative cancer care has partnered with Bupa to open new health clinics within Rutherford Cancer Centres to create a one-stop-shop journey for customers from diagnosis to treatment.

 

The move will give customers access to services such as private GP appointments, health assessments and physiotherapy.

 

Customers using Bupa's clinic will benefit from simple onward referrals. If symptoms of cancer are picked up in the Bupa Health Clinic, patients will be able to see Rutherford's cancer specialists within the cancer centres - which offer MRI and CT scans, mammograms and ultrasonograms - on the same day.

 

The first clinic opened at Rutherford's Cancer Centre North West in Liverpool on 8 November 2021. It will be followed by a second at the Rutherford Cancer Centre North East, Northumberland, in early 2022.  

 

Incorporating Bupa Health Clinics within its centres further expands the diversity of Rutherford's revenues beyond cancer care.

 

Mike Moran, CEO of Rutherford Health Plc, said:

"Expanding our relationship with Bupa to provide Bupa Health Clinics at our Rutherford Cancer Centres is an exciting step towards bringing better healthcare to more people. The one-stop clinic offering will enable access to our state-of-the-art diagnostics and treatments for those who need them, while also diversifying our business streams.

 

"That Bupa chose us to partner with to create new Bupa Health Clinics is a real endorsement of our offering, experienced team and the state-of-the-art, patient centred facilities we have built."

 

Dr Arun Thiyagarajan, Director at Bupa Health Clinics said:

"When people have cancer concerns, we know it's so important to move quickly, both to get the best prognosis or give them much needed peace of mind.  Our partnership with Rutherford Cancer Centres will help give people a quick and easy pathway from diagnosis to treatment, so we're delighted to be launching health clinics within their sites."

 

The Bupa Health Clinics will have their own entrances and Bupa branding, though will be run in partnership with Rutherford, whose expert team will provide staffing and management. Marketing and patient engagement will be driven by Bupa and the management of the clinics will be supported by Bupa infrastructure including operations, IT support, clinical governance etc.

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

-Ends-

 

For more information, please contact:

 

Rutherford Health plc

+44 (0) 16 3381 0661

Michael Moran, Chief Executive Officer
Marcus King, Finance Director

Investors@therutherford.com

  

 

Grant Thornton (Corporate Adviser)

+44 (0) 20 7383 5100

Colin Aaronson / George Grainger

 

 

 

Instinctif Partners

+44 207 457 2020

Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris

Rutherford@Instinctif.com

 

 

Media House International

07788 414 856 / 0207 710 0020

Ramsay Smith

ramsay@mediahouse.co.uk

 

 

Bupa

Laura Tompkins                                                

07595461287

                bupapressoffice@bupa.com

 

 

About Rutherford Health plc

Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in Wales, Reading, Northumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.

The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website: www.rutherfordhealth.com.

 

About Bupa

Bupa's purpose is helping people live longer, healthier, happier lives and making a better world.We are an international healthcare company serving over 31 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers.We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong SAR, Turkey, Brazil, Mexico, the US, Middle East and Ireland. We also have associate businesses in Saudi Arabia and India.

For more information, visit www.bupa.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBABFTMTBMBJB ]]>
TwitterFacebookLinkedIn